Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30416406 | 0.92 | CRBN (0.55) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL25252129 | 0.84 | CRBN (0.60) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL25213181 | 0.83 | CRBN (0.61) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30032311 | 0.83 | CRBN (0.63) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL23423465 | 0.83 | CRBN (0.63) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30133275 | 0.82 | CRBN (0.60) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL23860884 | 0.82 | CRBN (0.60) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL25375521 | 0.82 | CRBN (0.63) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL25215119 | 0.82 | CRBN (0.62) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30416584 | 0.82 | CRBN (0.62) | CRBNIKZF2IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-4188549-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CRBN 3187/4885IKZF2 3603/4885IKZF1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.